Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights

Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights

Abstract Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal dosing strategies and dose-dependent therapeutic mec...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Shi, Ziying Zhang, Song Mei, Zerui Wang, Zhe Xu, Weiqi Yao, Limin Liu, Mengqi Yuan, Yuefei Pan, Kaidi Zhu, Kai Liu, Fanglin Meng, Jiao Sun, Wenying Liu, Xiaohui Xie, Tengyun Dong, Lei Huang, Fanping Meng, Jun-Liang Fu, Yuanyuan Li, Chao Zhang, Xing Fan, Ming Shi, Yu Zhang, Yonggang Li, Wei-Fen Xie, Peng Zhang, Fu-Sheng Wang
Format: Article
Language:English
Published: Nature Publishing Group 2025-07-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02318-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-025-02318-4

Similar Items